- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03157401
Two Different Administration Methods of Tranexamic Acid on Perioperative Blood Loss During Total Hip Arthroplasty
Effects of Two Different Administration Methods of Tranexamic Acid on Perioperative Blood Loss During Total Hip Arthroplasty: a Prospective, Open-label, Randomized, Controlled Clinical Trial
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Background Total hip arthroplasty (THA) is extensively used in various hip diseases. Abundant blood supply at surgical area of bone tissue, intraoperative extensive cleaning, acetabular formation, femoral expansion, and medullary cavity and bone wound bleeding, will lead to extensive intraoperative and postoperative blood loss. The blood transfusion rate is high, which affects patients' rehabilitation. Previous studies have shown that 16%-69% patients required blood transfusion after first THA, which greatly affected patient's rehabilitation, and increased the risk of transfusion-related infection, hemolysis, immunosuppression, acute lung injury, and death. How to reduce perioperative blood loss in total hip arthroplasty has become a hot spot for joint surgeons.
Tranexamic acid as a synthetic antifibrinolytic drug is a synthetic analog of the amino acid lysine. Its mechanisms of action are the competitive inhibition of fibrinolytic zymogens, and noncompetitive inhibition of fibrinolytic enzymes. Tranexamic acid strongly inhibits plasmin-induced fibrin decomposition, reduces fibrinolytic system activity, to achieve local hemostasis and reduce bleeding (Appendix 1). However, the route of administration of tranexamic acid is diverse, and the best way to administer is not clear. A large number of studies have confirmed that during total knee arthroplasty and THA, intravenous application of tranexamic acid can significantly reduce postoperative blood loss, blood transfusion volume and blood transfusion rate. Intra-articular application of tranexamic acid can reduce the drainage volume of drainage tube, total blood loss, blood transfusion volume and blood transfusion rate after joint arthroplasty. Moreover, hemoglobin levels remarkably increase after surgery. More and more studies and meta-analysis have verified that tranexamic acid has a "target effect". Reasonable use of tranexamic acid does not increase the risk of deep venous thrombosis or pulmonary embolism after hip and knee arthroplasties. Simultaneously, tranexamic acid has a good potency ratio.
Adverse events
- To record adverse events during follow up, including incision pain, infection, hip pain, peripheral nerve injury, pulmonary embolism, lower extremity hematoma, deep vein thrombosis, and fixator falling off.
- If severe adverse events occur, investigators would report details, including the date of occurrence and measures taken to treat the adverse events, to the principle investigator and the institutional review board within 24 hours.
Data collection, management, analysis, open access
- Data collection: Case report forms were collected and processed using Epidata software (Epidata Association, Odense, Denmark). These data would be recorded electronically.
- Data management: Tengzhou Central People's Hospital, China would preserve all of the data regarding this trial. Only the project manager has the right to query the database file. This arrangement will not be altered.
- Data analysis: A professional statistician would statistically analyze the electronic database and create an outcome analysis report. An independent data monitoring committee would supervise and manage the trial data.
- Data open access: Anonymized trial data will be published at www.figshare.com.
Statistical analysis
- Statistical analysis would be performed using SPSS 19.0 software (IBM, Armonk, NY, USA) and would follow the intention-to-treat principle.
- Normally distributed measurement data would be expressed as means ± standard deviation and minimums and maximums. Non-normally distributed measurement data would be expressed as the lower quartile (q1) and median and upper quartiles (q3). Count data would be expressed as a percentage.
- The differences in hidden blood loss, dominant blood loss and mean blood loss in each group at intraoperative, postoperative 1 and 3 days would be compared using two-factor analysis of variance with repeated measures. Paired comparison of intergroup data would be conducted using least significant difference. Blood transfusion rate and incidence of adverse reactions in each group were compared using Pearson X2 test.
- The significance level would be α = 0.05.
Studientyp
Einschreibung (Voraussichtlich)
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Femoral head necrosis or femoral neck fracture patients undergoing the first unilateral THA
- Bilateral hips with indications for THA in patients with femoral head necrosis, but after arthroplasty on one side, the arthroplasty on the other side will be conducted when choosing a good time and physical condition allows.
- Average age: 62.52 years
- Sex ratio of males to females: 11:19
- Signed informed consent
Exclusion Criteria:
- Coagulation disorders and anemia
- History of infection on the affected extremity
- History of vascular embolization and long-term oral anticoagulant drugs
- Contraindications for tranexamic acid or anticoagulant drugs
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
intravenous infusion group
In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
|
In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
Andere Namen:
|
intra-articular injection group
In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
|
In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
Andere Namen:
|
control group
In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
|
In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery.
After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
hidden blood loss
Zeitfenster: at postoperative 1 and 3 days
|
Hidden blood loss was calculated by the circulation volume proposed by Gross, i.e., total erythrocyte loss is equal to preoperative total blood volume × (hematocrit preoperatively - hematocrit postoperatively 3 days).
|
at postoperative 1 and 3 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Dominant blood loss
Zeitfenster: at intraoperative, postoperative 1 and 3 days
|
Dominant blood loss includes intraoperative blood loss and postoperative blood loss.
Intraoperative blood loss was quantified by measuring irrigation fluid and weight measurement of surgical sponges.
Postoperative blood loss was quantified by measuring wound drainage volume and weight measurement of surgical sponges.
|
at intraoperative, postoperative 1 and 3 days
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Zhenyang Hou, Master, Tengzhou Central People's Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- TengzhouCPH_01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Totale Hüftendoprothetik
-
University of North Carolina, Chapel HillNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)AbgeschlossenKnieendoprothetik, total | Knieprothese, totalVereinigte Staaten
-
Hospices Civils de LyonRekrutierungKnieendoprothetik, totalFrankreich
-
Smith & Nephew, Inc.Aktiv, nicht rekrutierendKnieendoprothetik, totalVereinigte Staaten, Australien, Kanada, Belgien, Spanien
-
Bispebjerg HospitalAbgeschlossen
-
Steadman Philippon Research InstituteRekrutierungKnieendoprothetik, totalVereinigte Staaten
-
ExactechNoch keine RekrutierungHüftendoprothetik, total
-
ExactechRekrutierungKnieendoprothetik, totalVereinigte Staaten
-
University of Missouri-ColumbiaAbgeschlossenKnieendoprothetik, totalVereinigte Staaten
-
University of PennsylvaniaAbgeschlossenKnieendoprothetik, totalVereinigte Staaten
-
Ulrik GrevstadAbgeschlossenKnieendoprothetik, totalDänemark
Klinische Studien zur intravenous infusion group
-
Hui-Hsun ChiangAbgeschlossenErziehungsprobleme | Pflege | Gewalt am ArbeitsplatzTaiwan
-
University of Illinois at ChicagoPatient-Centered Outcomes Research Institute; University of ChicagoRekrutierungSchwangerschaftskomplikationen | Patientenbindung | Muster der mütterlichen FürsorgeVereinigte Staaten
-
University of LisbonAssociacao Protectora dos Diabeticos de PortugalAbgeschlossen
-
Nationwide Children's HospitalBeendetPCO-Syndrom | PCOSVereinigte Staaten
-
Centre Hospitalier Universitaire de NīmesBeendet
-
Universidade Federal de Santa MariaRekrutierungParodontitis | Parodontale Erkrankungen | Motivierende GesprächsführungBrasilien
-
Universitat Jaume IAbgeschlossenDepression | AngststörungenSpanien
-
The Policy & Research GroupMathematica Policy Research, Inc.; The Office of Adolescent Health, HHSAbgeschlossen
-
University of EdinburghNHS LanarkshireAbgeschlossen
-
Baylor Research InstituteUniversity of Texas Southwestern Medical Center; National Institute on Disability...Aktiv, nicht rekrutierendSchädel-Hirn-TraumaVereinigte Staaten